These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35115074)

  • 21. Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.
    Brusa L; Orlacchio A; Stefani A; Galati S; Pierantozzi M; Iani C; Mercuri NB
    Funct Neurol; 2013; 28(2):101-5. PubMed ID: 24125559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
    Liashchenko EA; Skripkina NA; Levin OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Management of levodopa-induced dyskinesia].
    Rascol O; Ferreira JJ; Payoux P; Brefel-Courbon Ch; Montastruc JL
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S117-24. PubMed ID: 12690671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.
    Walker RW; Howells AR; Gray WK
    Parkinsonism Relat Disord; 2011 Jan; 17(1):27-9. PubMed ID: 21051272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
    Merims D; Ziv I; Djaldetti R; Melamed E
    Lancet; 1999 May; 353(9166):1764-5. PubMed ID: 10347995
    [No Abstract]   [Full Text] [Related]  

  • 26. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White matter alterations in Parkinson's disease with levodopa-induced dyskinesia.
    Ogawa T; Hatano T; Kamagata K; Andica C; Takeshige-Amano H; Uchida W; Saito Y; Shimo Y; Oyama G; Umemura A; Iwamuro H; Ito M; Hori M; Aoki S; Hattori N
    Parkinsonism Relat Disord; 2021 Sep; 90():8-14. PubMed ID: 34325387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
    Merims D; Ziv I; Sherki Y; Djaldetti R; Melamed E
    Neurol Neurochir Pol; 2001; 35 Suppl 3():65-8. PubMed ID: 12001656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dyskinesias and levodopa therapy: why wait?
    Matarazzo M; Perez-Soriano A; Stoessl AJ
    J Neural Transm (Vienna); 2018 Aug; 125(8):1119-1130. PubMed ID: 29428995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Chaudhuri KR; Jenner P; Antonini A
    Mov Disord; 2019 Jun; 34(6):816-819. PubMed ID: 30983023
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease.
    Müller T; Woitalla D; Russ H; Hock K; Haeger DA
    J Neural Transm (Vienna); 2007; 114(8):1023-6. PubMed ID: 17417738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Understanding and treating levodopa-induced dyskinesias].
    Hadj Tahar A; Bédard PJ
    Tunis Med; 1998 Dec; 76(12):437-47. PubMed ID: 10093483
    [No Abstract]   [Full Text] [Related]  

  • 34. Abnormal bidirectional plasticity-like effects in Parkinson's disease.
    Huang YZ; Rothwell JC; Lu CS; Chuang WL; Chen RS
    Brain; 2011 Aug; 134(Pt 8):2312-20. PubMed ID: 21742734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
    Tran TN; Vo TNN; Frei K; Truong DD
    J Neural Transm (Vienna); 2018 Aug; 125(8):1109-1117. PubMed ID: 29971495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A; Nagy H; Wacha J; Bereczki D; Takáts A
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Vacca L; Olanow CW
    Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
    Rocha MS; Andrade LA; Ferraz HB; Borges V
    Arq Neuropsiquiatr; 1995 Dec; 53(4):737-42. PubMed ID: 8729765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 40. Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice.
    Espay AJ; Lang AE
    JAMA Neurol; 2017 Jun; 74(6):633-634. PubMed ID: 28459962
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.